{"nctId":"NCT00461032","briefTitle":"Montelukast Back to School Asthma Study (0476-340)","startDateStruct":{"date":"2006-06"},"conditions":["Asthma"],"count":1162,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: montelukast"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo"]}],"interventions":[{"name":"montelukast","otherNames":[]},{"name":"Comparator: Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female non-smoking Participants, ages 6 to 14 years, with chronic asthma, history of at least one asthma exacerbation associated with a cold within the past year and a documented history of asthma that required treatment with any asthma medication within 6 months prior to Visit 1\n\nExclusion Criteria:\n\n* Participant cannot have any other acute or chronic pulmonary disorder, or hospitalization for asthma more than three times within one year prior to signing informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"14 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Percentage of Days With Worsening Asthma (as Measured on Daily Diaries) in Pediatric Asthmatic Participants","description":"A day of worsening asthma is a day with: increase from baseline in β-agonist use (\\> 70% and a min increase of 2 puffs); \\> 50% increase from baseline in daytime symptoms score; awake \"all night\"; increase from baseline in inhaled corticosteroid use ≥ 100% or oral corticosteroid rescue for worsening asthma; or unanticipated healthcare utilization.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.23","spread":null},{"groupId":"OG001","value":"24.26","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Occurrence of One or More Health Care Utilizations (as Measured on Daily Diaries)","description":"Health care utilization is defined as unanticipated asthma care in an office or clinic, emergent or hospital setting.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"406","spread":null},{"groupId":"OG001","value":"411","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Days With Increased β-agonist Use by >70% and a Minimum Increase of 2 Puffs From Baseline (as Measured on Daily Diaries) in Pediatric Asthmatic Participants","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.02","spread":null},{"groupId":"OG001","value":"6.04","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Days With Increased Daytime Asthma Symptom Score by >50% From Baseline (as Measured on Daily Diaries) in Pediatric Asthmatic Participants","description":"Daytime asthma symptom score was calculated as the sum of the responses (0 (best) to 5 (worst)) to three daytime symptom questions.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null},{"groupId":"OG001","value":"16.03","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":566},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Asthma","Sinusitis","Pharyngolaryngeal pain"]}}}